So far, there is a line of CTGF-targeted drugs in clinical trials (51, 52), most of which are designed for treating fibrosis-related diseases, while ocaperidone and pamrevlumab also include pancreatic cancer as their indications (53). This evidence concerns the gene CCN2 and familial pancreatic carcinoma.